Table 2.
Incidence of most frequent treatment-emergent adverse events.
| Adverse event, n (%) | CS42 (n = 156) | CS21 (n = 207) |
|---|---|---|
| Any | 113 (72) | 144 (70) |
| Injection-site pain | 34 (22) | 55 (27) |
| Hyperhidrosis | 14 (9) | – |
| Injection-site erythema | 13 (8) | 35 (17) |
| Constipation | 13 (8) | 11 (5) |
| Upper respiratory tract infection | 12 (8) | 3 (1) |
| Nocturia | 10 (6) | 5 (2) |
| Hot flusha | 5 (3) | 45 (22) |
| Injection site swelling | 4 (3) | 10 (5) |
| ALT increase | 3 (2) | 16 (8) |
| Hypertension | 1 (<1) | 12 (6) |
ALT, alanine aminotransferase.
a
Five (3%) patients also reported flushing in CS42.